Gut microbiome, T cell subsets, and cytokine analysis identify differential biomarkers in tuberculosisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study explored how gut microbiota, T-cell subsets, and cytokines interact across different stages of tuberculosis (TB). Stool underwent 16S rDNA sequencing analyzed in QIIME2, with LEfSe and random forest models to find differential taxa and biomarkers. Cytokines were measured by ELISA and lymphocyte subsets by flow cytometry, then correlated with microbiota using Spearman analysis.
Who was studied?
The study enrolled 90 participants in China: 30 healthy controls, 30 initial TB patients, and 30 recurrent (retreatment) TB patients. Groups were matched on age, sex, and clinical symptoms. Controls had no respiratory illness or TB contact, and no one had taken antibiotics, prebiotics, or probiotics in the prior month. TB patients had higher white blood cell counts and lower hemoglobin and lymphocyte percentages than controls (P below 0.05).
What were the most important findings?
The three groups differed in 44 taxa and 61 metabolic pathways. Initial TB was enriched for Lachnospiraceae and related taxa, while recurrent TB was enriched for Proteobacteria and Enterobacteriaceae. A 20-genus random forest panel distinguished patients from controls, with areas under the ROC curve of 0.807 and 0.715. Alpha-diversity indices differed significantly (for example Shannon P 0.00013). Recurrent-TB patients had the lowest CD4 counts and CD4/CD8 ratios, higher CD8 and NKT cells, higher IL-6, and lower IL-4 versus controls (P below 0.05).
What are the greatest implications of this study?
The results suggest gut microbiota, T-cell subsets, and cytokines shift together across TB stages, supporting a gut-lung axis in disease. Microbial and immune biomarkers might help distinguish TB stages and guide new therapeutic strategies, such as microbiota modulation. The authors caution this was observational. They did not validate taxa in mice or analyze lung microbiota, so mechanistic and causal roles remain unproven.